References
Hutchinson J (1868) Outbreak of a large crop of moles. Remarks as to possible connection with melanosis. J Cutan Med Dis Skin 1:170–171
Amitay-Laish I, Stemmer SM, Lacouture ME (2011) Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther 24(4):386–395. https://doi.org/10.1111/j.1529-8019.2011.01431.x
Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V (2004) Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 15(2):358–359
Bovenschen HJ, Tjioe M, Vermaat H, de Hoop D, Witteman BM, Janssens RW, Stoof TJ, van de Kerkhof PC (2006) Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol 154(5):880–884. https://doi.org/10.1111/j.1365-2133.2006.07189.x
Kim M, Yoon YH, Lee JH, Kim DW, Park HJ (2017) Eruptive melanocytic naevi caused by radotinib therapy in patients with chronic myeloid leukaemia: 10 cases and a literature review. Acta Derm Venereol 97(1):115–116. https://doi.org/10.2340/00015555-2475
Perry BM, Nguyen A, Desmond BL, Blattner CM, Thomas RS, Young RJ (2016) Eruptive nevi associated with medications (ENAMs). J Am Acad Dermatol 75(5):1045–1052. https://doi.org/10.1016/j.jaad.2016.04.064
Won KH, Jo SY, Lee YJ, Chang SE (2016) Radotinib-induced lentiginosis: a report of an adverse cutaneous reaction associated with a tyrosine kinase inhibitor. Clin Exp Dermatol 41(2):162–165. https://doi.org/10.1111/ced.12706
Woo YR, Kim JS, Kim DW, Park HJ (2017) Development of dysplastic nevus during radotinib therapy in patients with chronic myeloid leukemia. Indian J Dermatol Venereol Leprol 83(6):704–707. https://doi.org/10.4103/ijdvl.IJDVL_1030_16
Kwak JY, Kim SH, Oh SJ, Zang DY, Kim H, Kim JA, Do YR, Kim HJ, Park JS, Choi CW, Lee WS, Mun YC, Kong JH, Chung JS, Shin HJ, Kim DY, Park J, Jung CW, Bunworasate U, Comia NS, Jootar S, Reksodiputro AH, Caguioa PB, Lee SE, Kim DW (2017) Phase III clinical trial (RERISE study) results of efficacy and safety of Radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia. Clin Cancer Res 23(23):7180–7188. https://doi.org/10.1158/1078-0432.Ccr-17-0957
Eskazan AE, Keskin D (2017) Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update. Ther Adv Hematol 8(9):237–243. https://doi.org/10.1177/2040620717719851
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Consent
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
Rights and permissions
About this article
Cite this article
Park, E., Jue, MS. Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review. Ann Hematol 98, 533–535 (2019). https://doi.org/10.1007/s00277-018-3444-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-018-3444-0